Scope and Claims Analysis for US Patent 6,166,042: Pioglitazone/Troglitazone Plus Biguanide Methods for Treating Glycometabolism Disorders

US 6,166,042 claims a treatment method for “glycometabolism disorders” in mammals using a two-drug combination: an insulin sensitivity enhancer (a thiazolidinedione or related class defined by a broad structural formula) administered together with a biguanide (phenformin, metformin, buformin; with metformin called out repeatedly). The claim set is anchored to specific exemplified insulin sensitivity enhancers including pioglitazone and troglitazone, but it also uses a genus claim (formula-defined) that can extend coverage to additional insulin-sensitizing compounds within the structural definition, plus claim variants on salt forms, substitution patterns, and administration format (admixture vs separate dosing).

For US regulatory and commercial impact: this is a method-of-use patent directed to combination therapy. It does not claim a formulation product per se, but it does cover how the drugs are administered (including combined admixture), which becomes relevant to FDA labeling design, prescribing instructions, and generic or brand launch strategy where combination regimens are marketed.

What patents protect glycometabolism disorder treatment using pioglitazone (or thiazolidinediones) plus metformin in the US?

US 6,166,042’s core protection is method-of-treatment using an insulin sensitivity enhancer + biguanide. The claim language uses two tiers:

Combination method claim (Claim 1)
A “method for treating glycometabolism disorders” in a mammal needing treatment by administering a therapeutically effective amount of:
- an insulin sensitivity enhancer and
- a biguanide in combination.
Insulin sensitivity enhancer structural genus (Claim 2 and dependent claim set)
Claim 2 defines the insulin sensitivity enhancer by a detailed Markush-style chemical formula with multiple variable regions:
- R is optionally substituted hydrocarbon or heterocyclic group
- Y can be --CO--, --CH(OH)--, or --NR3-- (with R3 an optionally substituted alkyl)
- m is 0 or 1
- n is 0, 1, or 2
- X is CH or N
- A is a bond or C1-7 divalent aliphatic hydrocarbon
- Q is oxygen or sulfur
- R1 is hydrogen or alkyl
- ring E may be optionally substituted (1–4 substituents) with flexible cyclization rules via L and M
Biguanide scope (Claim 11 onward)
Biguanides are explicitly limited to phenformin, metformin, and buformin, with metformin called out specifically in Claims 12 and 13.

Directly named insulin sensitivity enhancers in the claims include:

Pioglitazone (and its hydrochloride) in Claim 10
Troglitazone in Claim 14
5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]-methyl]-2,4-thiazolidinedione (and salts) in Claim 15

Administration mode coverage:

Admixture dosing (Claim 16): insulin sensitivity enhancer and biguanide mixed then administered
Independent dosing (Claim 17): each administered separately

Claim 1: What exactly is being claimed?

Claim 1 is a method-of-treatment using combination therapy. It is not limited to any specific biguanide or any specific insulin sensitivity enhancer in Claim 1 itself; those limitations appear in dependent claims. Practically, Claim 1 establishes the broadest combination frame: any insulin-sensitizing enhancer that later dependent claims describe as encompassed, combined with any biguanide in the defined class.

Claim 2: How broad is the insulin sensitivity enhancer genus?

Claim 2 is a chemical Markush genus constrained by:

ring heteroatoms (Q is O or S; X is CH or N)
defined structural attachment points (A, L, M)
configurable substituents (R, ring E optional substituents)
allowed Y functional group set (--CO--, --CH(OH)--, --NR3--)
variable index parameters m and n (0/1 for m; 0/1/2 for n)

This is broad enough to capture multiple thiazolidinedione and related scaffold variants, and narrow enough to require matching the scaffold-defined positions of Q, X, A, and the functional group allowances. The genus claim is the key lever for extending enforcement beyond the named examples (pioglitazone, troglitazone) to structurally similar insulin sensitivity enhancers.

Claim 10/14/15: Where do the claims become product-identifying?

Claim 10 pins the insulin sensitivity enhancer to pioglitazone or hydrochloride.
Claim 14 pins to troglitazone.
Claim 15 pins to a specific thiazolidinedione substitution pattern with a pyridylamino-ethoxy substituent and thiazolidinedione core.

These dependent claims are important because they:

strengthen validity arguments by offering clear anchor species within the genus
provide enforcement coverage even if a competitor tries to argue “outside genus” positioning based on small structural differences.

Claim 11/12/13: Biguanide limitations that matter for enforcement

Claim 11: biguanide is phenformin, metformin, or buformin
Claim 12: biguanide is metformin
Claim 13: insulin sensitivity enhancer is pioglitazone and biguanide is metformin

Claim 13 is the most commercially pointed combination claim for the modern market because pioglitazone is paired with metformin as a standard diabetes regimen.

Claim 16 vs 17: What prevents “workaround” on administration format?

Many combination method patents include dosing format limitations that can be avoided by giving drugs separately. Here, the patent covers both:

admixture dosing (Claim 16) and
separate dosing (Claim 17)

That collapses a common design-around path used in product-label and patient regimen structuring.

Which combinations are explicitly covered: pioglitazone + metformin, troglitazone + metformin, and other biguanides?

Explicit combination coverage by dependent claim structure:

Pioglitazone + metformin: Claim 13
Troglitazone + biguanide: Claim 14 plus Claim 11/12/13 logic depending on which biguanide is used (troglitazone appears as the insulin sensitivity enhancer in Claim 14; the biguanide is captured via Claim 11/12 within the dependency chain for Claim 1/11/12 where applicable).
Named thiazolidinedione + biguanide: Claim 15 plus Claim 11/12.

Biguanide substitution risk: Because biguanides are explicitly limited to phenformin/metformin/buformin, switching from metformin to phenformin or buformin would remain within the patent scope if the other claim elements are met. From a litigation perspective, that matters because it reduces argument pathways based on “not metformin.”

Operationally important scope point: Even if Claim 1 is broad, the patent includes explicit dependent claims that map to commercially relevant regimens. That increases enforceability leverage because a court can land on the narrower dependent claims even if the genus is contested.

How strong is US 6,166,042’s patent estate based on claim structure (genus + anchor species + dosing-format variants)?

This patent’s strength derives from three structural features:

Genus claim on insulin sensitivity enhancer (Claim 2)
- Enables coverage across a class of compounds defined by structural parameters rather than only on named molecules.
- Makes it harder for an accused infringer to argue “we didn’t use pioglitazone.”
Anchor species dependent claims (Claims 10, 14, 15)
- Provide concrete examples that align with widely known thiazolidinediones.
- Reduce reliance on proving genus interpretation for every alleged compound.
Combination administration in two formats (Claims 16 and 17)
- Covers both a physical admixture and separate dosing.
- Reduces “labeling and packaging workaround” defenses.

Claim construction pressure points

The most likely technical/legal pressure points in enforcement are:

Whether an accused “insulin sensitivity enhancer” fits the Claim 2 structural formula (Markush interpretation and substitution matching).
Whether “glycometabolism disorders” is read as sufficiently definite and whether the accused regimen’s indication aligns with the claim’s treatment concept.

Enforcement posture implication

Because the patent includes explicit dependent claims for pioglitazone and metformin, enforcement does not need to rely solely on the broadest genus. That generally improves practical litigation posture versus patents that only claim broad genera without anchored examples.

What formulations are protected: mixed admixtures vs co-administration with separate products?

Although US 6,166,042 is framed as a method rather than a composition patent, it expressly covers administration scenarios that resemble formulation-level considerations:

Admixture administration (Claim 16)
The insulin sensitivity enhancer and biguanide are mixed to form an admixture, then administered.
Separate administration (Claim 17)
The insulin sensitivity enhancer and biguanide are not mixed, administered independently.

Practical consequence:
A competitor cannot fully avoid risk by selling separate tablets and relying on the absence of a combined composition product. Claim 17 covers that scenario as long as the regimen is a method of treating “glycometabolism disorders” with the combination in a therapeutically effective amount.

When does US 6,166,042 lose exclusivity and how does that affect generic entry risk?

No expiration date, filing date, patent term adjustments, terminal disclaimer terms, or continuation history are provided in the prompt. Without those facts, exclusivity timing and generic launch windows cannot be calculated from the claim text alone.

What Orange Book status applies to US 6,166,042?

No Orange Book listing, patent-to-product mapping, or FDA publication/patent code details are provided in the prompt. Orange Book status cannot be determined from claim text alone.

What Paragraph IV challenges and litigation risks exist for this patent?

The prompt does not provide any litigation docket details (e.g., case numbers, parties, PTAB outcomes, district court findings, settlement dates, or any Paragraph IV notice data). Without that, litigation risk mapping cannot be derived.

How does US 6,166,042 compare with modern combination-patent patterns for diabetes therapy (TZD + biguanide)?

US 6,166,042 follows a common late-1990s/early-2000s US combination patent blueprint:

Treating a metabolic disorder using two drug categories
A combination method claim with class-defining chemical genus for one component
Explicit inclusion of key marketed molecules
Explicit coverage for dosing format variants

Compared with patents that claim only a specific fixed combination or only a single salt/form, this one:

adds chemical genus flexibility for the insulin-sensitizing component,
adds explicit pioglitazone/troglitazone coverage,
and covers admixture and non-admixture administration.

That combination pattern tends to broaden both claim reach and enforcement leverage against generic combinations, because it is not limited to a specific formulation product or a single dosing strategy.

Key claim-by-claim scope map (what each claim adds beyond Claim 1)

Claim	Incremental scope effect	Practical enforcement meaning
1	Combination method: insulin sensitivity enhancer + biguanide for glycometabolism disorders	Establishes broad method frame even before specifying which drugs
2	Insulin sensitivity enhancer restricted to formula-defined genus; includes pharmacologically acceptable salts	Defines chemical boundary for “insulin sensitivity enhancer” category
3	R is optionally substituted heterocycle	Narrows genus subset
4	m = 0	Narrows to a subset of genus structures
5	X = CH	Narrows to subset
6	R1 = hydrogen	Narrows to subset
7	Partial formula constraints on R2 (H/alkyl/hydroxyl/halogen/acyl/nitro/amino)	Adds substitution pattern limitation
8	L and M = hydrogen	Narrows to subset
9	Explicit subset with R = pyridyl/oxazolyl/thiazolyl; specific A, R1, and partial formula definitions	Moves toward concrete scaffolds
10	Insulin sensitivity enhancer = pioglitazone or hydrochloride	Anchor species for modern market pairing
11	Biguanide = phenformin/metformin/buformin	Defines biguanide class boundary
12	Biguanide = metformin	Anchor species for modern regimen
13	Pioglitazone + metformin combination method	Most commercially pointed dependent claim
14	Insulin sensitivity enhancer = troglitazone	Additional anchor species
15	Specific thiazolidinedione derivative with pyridylaminoethoxy substituent	Third anchor species example
16	Admixture formed then administered	Covers combined dosing product behavior
17	Administered independently	Covers separate tablets regimen and co-prescribing scenarios

Key Takeaways

US 6,166,042 is a combination method patent covering treatment of “glycometabolism disorders” using an insulin sensitivity enhancer defined by a broad structural genus plus a biguanide limited to phenformin/metformin/buformin.
The claim set includes anchor species for pioglitazone (incl. hydrochloride), troglitazone, and a specific thiazolidinedione derivative, alongside the genus definition that can extend coverage beyond those named examples.
It covers both admixture dosing (Claim 16) and independent administration (Claim 17), reducing common design-around strategies based on separate product dosing.
The most commercially direct dependent coverage is pioglitazone + metformin (Claim 13).

FAQs

Does US 6,166,042 require the drugs to be mixed together to infringe?

No. Claim 17 covers independent dosing where the insulin sensitivity enhancer and biguanide are administered separately.

Is phenformin or buformin covered if metformin is not used?

Yes. Claim 11 expressly includes phenformin and buformin as biguanides within the combination method.

Are only pioglitazone-based regimens protected?

No. Claim 2 provides a broad formula-defined genus for insulin sensitivity enhancers, with pioglitazone as one anchor species in Claim 10.

Can a competitor argue that a different insulin sensitivity enhancer avoids coverage?

Coverage depends on whether the alternative compound fits the Claim 2 structural definition. Claims 10, 14, and 15 add anchor coverage for specific species, strengthening the overall claim set.

Is the patent limited to a specific salt form of metformin?

No. Metformin is named as the biguanide in Claim 12, and the claim text provided does not introduce a salt restriction for the biguanide component.

References (APA)

United States Patent 6,166,042.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	7-153500	Jun 20, 1995

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0861666	⤷ Start Trial	91298	Luxembourg	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	300258	Netherlands	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	SPC 038/2006	Ireland	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	07C0006	France	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,166,042

Summary for Patent: 6,166,042